Home/Pipeline/MYC/KRAS Degrader Program

MYC/KRAS Degrader Program

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

Grove Biopharma

About Grove Biopharma

Grove Biopharma is a private, pre-clinical-stage biotech developing a breakthrough platform for intracellular drug delivery. Its core technology, Bionic Biologics™, uses precision polymerization to create synthetic, cell-permeable polymers that can engage challenging intracellular protein-protein interaction targets. The company has demonstrated proof-of-concept across several high-value targets, including MYC and KRAS, and is backed by a $30 million Series A financing to advance its pipeline in oncology, neurodegenerative diseases, and rare disorders.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases Rare Disorders Cardiovascular

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active